CEO Kevin Finney describes the rationale for using a TRβ agonist and how this program leverages Autobahn's brain-targeting chemistry platform. Plus, how the funding will also allow the company to advance a S1P receptor modulator.
Also look for unique social pages for BiotechTV U.
Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.
.png){kind=logo}
